Evidence map›Paper›PMID 38100005›Full record

ArticleJournal of patient-reported outcomes2023

Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L.

Ivana F Audhya, Shelagh M Szabo, Andrea Bever, Fiona O'Sullivan, Daniel C Malone, David Feeny, Peter Neumann, Susan T Iannaccone, P Jayasinghe, Katherine L Gooch

Open access · goldAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Ivana F AudhyaSarepta Therapeutics, Inc., Cambridge, MA, USA.
Shelagh M SzaboBroadstreet HEOR, 201-343 Railway St, Vancouver, BC, V6A 1A4, Canada. sszabo@broadstreetheor.com.ORCID 0000-0002-9044-3192
Andrea BeverBroadstreet HEOR, 201-343 Railway St, Vancouver, BC, V6A 1A4, Canada.
Fiona O'SullivanBroadstreet HEOR, 201-343 Railway St, Vancouver, BC, V6A 1A4, Canada.
Daniel C MaloneThe University of Utah, Salt Lake City, UT, USA.
David FeenyMcMaster University, Hamilton, ON, Canada.
Peter NeumannTufts Medical Center, Boston, MA, USA.
Susan T IannacconeThe University of Texas Southwestern, Dallas, TX, USA.
P JayasingheBroadstreet HEOR, 201-343 Railway St, Vancouver, BC, V6A 1A4, Canada.
Katherine L GoochSarepta Therapeutics, Inc., Cambridge, MA, USA.
Vancouver Coastal Health · CASarepta Therapeutics (United States) · USMcMaster University · CAThe University of Texas Southwestern Medical Center · USTufts Medical Center · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe progression of Duchenne muscular dystrophy (DMD) is characterized by loss of ambulation, respiratory insufficiency, cardiomyopathy, and early mortality. DMD profoundly impacts health-related quality-of-life (HRQoL). However, few health state utility data exist; published utilities tend to be derived from small samples for a limited number of health states and are often based on caregiver-reported patient health status. This study estimated utility values for varied clinical and functional health states in DMD, based on patient-reported health status.

methodsIndividuals with DMD in the US aged 12-40 years completed the EQ-5D (5-level) and Health Utilities Index (HUI) preference-based instruments. Based on responses to a clinical questionnaire, participants self-classified into functional health states according to level of lower and upper limb function, use of respiratory support, and presence of cardiomyopathy. Mean [standard deviation (SD)] utility and EQ-5D visual analogue scale (VAS) scores were estimated according to health state; and median (interquartile range) attribute levels calculated to understand which domains of health are most severely affected in DMD.

resultsOf 63 males with DMD, mean (SD) age was 19.8 (6.1) years and 11 (17.5%) were ambulatory. Mean (SD) utility values were 0.92 (0.08; HUI2), 0.84 (0.20; HUI3), and 0.84 (0.13; EQ-5D) for ambulatory patients without cardiomyopathy (n = 10). For non-ambulatory patients with moderately impaired upper limb function, night and daytime ventilation without cardiomyopathy, mean (SD) utilities were 0.49 (0.07) for the HUI2, 0.16 (0.15) for the HUI3 and 025 (0.14) for the EQ-5D. Mean (SD) VAS scores for the same health states were 91 (9) and 83 (21), respectively. In addition to impairments in mobility/ambulation, and self-care, attributes like usual activities and pain also showed notable effects of DMD.

conclusionsIn DMD, although a relationship between disease progression and HRQoL is observed, there is large variability in utility within functional health states, and across instruments. Utility values for less severe non-ambulatory health states described by level of upper limb function are novel. These utility values, derived based on direct patient feedback rather than from caregiver report, are relevant to individuals of varying functional statuses and augment scarce DMD-specific utility data.

Indexed as

CardiomyopathiesMuscular Dystrophy, DuchenneHumansMalePainQuality of LifeRespirationDMDDuchenneEQ-5DHUIUtility

Identifiers

PMID38100005
PMCPMC10724100
OpenAlexW4389789011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.